AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase 3 clinical trial titled ‘DESTINY-Lung04′ to evaluate the efficacy and safety of Trastuzumab Deruxtecan as a first-line treatment for patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) with HER2 mutations. The study aims to determine if this treatment can extend patients’ lives or delay disease progression compared to the standard of care.
Intervention/Treatment: The trial tests Trastuzumab Deruxtecan, an experimental drug administered via intravenous infusion, against a standard care regimen of cisplatin or carboplatin, pembrolizumab, and pemetrexed.
Study Design: This is an open-label, randomized, parallel-assignment trial with no masking. Participants are randomly assigned to receive either the experimental drug or standard care, focusing on treatment efficacy.
Study Timeline: The study began on October 28, 2021, and is currently recruiting participants. The last update was submitted on July 7, 2025, indicating ongoing progress.
Market Implications: Positive results from this study could significantly impact AstraZeneca’s stock performance, enhancing investor confidence. Success in this trial may position AstraZeneca favorably against competitors in the oncology market, particularly in treatments targeting HER2 mutations.
The study is ongoing, with further details available on the ClinicalTrials portal.